Related Experiment Video

Updated: May 22, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Resistance Mechanisms of Alectinib in ALK-Positive Non-Small Cell Lung Cancer and Therapeutic Strategies

Yanru Zhao1,2, Chang He1,2, Juanjuan Xiao1,2,3,4

  • 1Translational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng, 475000, China.

Current Cancer Drug Targets
|May 21, 2026
PubMed

Insights

Alectinib improves outcomes for Anaplastic Lymphoma Kinase (ALK)-positive Non-Small Cell Lung Cancer (NSCLC). Understanding resistance mechanisms is key to developing new strategies for ALK-positive NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anaplastic Lymphoma Kinase (ALK) fusion genes drive a subset of Non-Small Cell Lung Cancer (NSCLC).
  • Alectinib, a potent ALK-Tyrosine Kinase Inhibitor (TKI), offers significant clinical benefit in first-line ALK-positive NSCLC.
  • Resistance to alectinib develops in approximately 50% of patients within two years, necessitating further therapeutic strategies.

Purpose of the Study:

  • To review the clinical efficacy and value of alectinib in treating ALK-positive NSCLC.
  • To elucidate the diverse mechanisms underlying acquired resistance to alectinib.
  • To outline current and emerging mechanism-driven therapeutic strategies for overcoming resistance.

Main Methods:

  • Literature review of preclinical and clinical studies on alectinib and ALK-positive NSCLC.
  • Analysis of reported resistance mechanisms, including genetic alterations and pathway activations.
  • Synthesis of data on next-generation TKIs, combination therapies, immunotherapy, and repurposed agents.

Main Results:

  • Alectinib demonstrates high efficacy and CNS penetration, improving prognosis for ALK-positive NSCLC patients.
  • Resistance mechanisms are multifaceted, involving ALK-dependent mutations, activation of bypass signaling pathways, and histological transformation.
  • Emerging strategies show promise in preclinical and early clinical settings.

Conclusions:

  • Alectinib remains a cornerstone therapy for ALK-positive NSCLC, but resistance is a significant clinical challenge.
  • Tailored treatment approaches, guided by dynamic monitoring (e.g., ctDNA liquid biopsy) and genomic profiling, are crucial for optimizing patient outcomes.
  • Continued research into resistance mechanisms and novel therapeutic combinations is essential for advancing care.
Keywords:
Alectinibanaplastic lymphoma kinase (ALK)mech-anism-driven strategies.non-small cell lung cancer (NSCLC)resistance mechanisms

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...